You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. High Temperature High Resolution in-situ Differential Pressure Sensor

    SBC: Innoveering, LLC            Topic: 90105

    Chemical manufacturers require high accuracy and high sensitivity pressure sensors to efficiently monitor the various manufacturing systems and processes in the chemical plant, to ensure any changes proceed in a safe and reliable manner, adhering to expected standards and practices. In addition, NIST has a need for highly accurate absolute and differential pressure measurements, especially for det ...

    SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology
  3. A microchip to analyze trafficking leukocytes in Alzheimer’s disease patients

    SBC: IsoPlexis            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD is one of the most common neurodegenerative diseases that lead to detrimental outcomes such as progressive memory deficit and cognitive impairment Although it is expected that the prevalence of AD will double over the next years currently no widely accepted molecular biomarkers for early detection or non invasive monitoring ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Sylvatica I Corps Commercialization Jan High Subzero Equilibrium VCA Cryopreservation

    SBC: Sylvatica Biotech, Inc.            Topic: R

    DESCRIPTION provided by applicant This program targets the long term preservation of vascularized composite tissues for both autologous and allotransplantation VCA such as of e g muscle flaps digits faces and whole limbs to radically improve restorative and reconstructive medicine We have conceived an integrated two pronged approach in which we will develop new nature inspired and furt ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel TLR Agonist Based Adjuvant for Poliovirus Vaccine

    SBC: BUFFALO BIOLABS, LLC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Antiviral vaccines remain the largest segment of the rapidly growing global vaccine market Despite near complete eradication of poliovirus through vaccination efforts continued need for inactivated polio vaccine IPV is projected to reach million doses per year worldwide Among major obstacles to widespread use of the current IPV formulation are its high cost and in ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Control Kit for Latent HIV Diagnostics

    SBC: Jan Biotech, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Health Problem Well over million in the U S and million people globally are infected with HIV With highly active or combination anti retroviral therapy HAART cART HIV AIDS becomes a chronic condition Unfortunately HAART is not a cure if treatment is stopped HIV virus production rapidly rebounds and leads to full blown HIV AIDS HAART fails ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Lyme disease caused by infection with Borrelia burgdorferi is the most common vector borne infectious disease in North America and Europe Early disease can be effectively cured with antibiotics however untreated late disseminated infection can result in permanent damage to the nervous and musculoskeletal systems Therefore early diagnosis is critical for ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Peptide-based Multiplex Assay for Lyme disease Serodiagnosis

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant We propose to develop a more sensitive specific multiplex serologic assay for the diagnosis of Lyme disease LD LD is the most common vector borne infectious disease in the United States and as such it is a significant public health concern The disease affects multiple organ systems including musculoskeletal skin and nervous system and is included in the ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. A product for osteoarthritis treatment and prevention

    SBC: NEW YORK R&D CENTER FOR TRANSLATIONAL MEDICINE AND THERAPEUTICS, INC.            Topic: R

    DESCRIPTION provided by applicant Osteoarthritis OA is the most common form of arthritis and the leading cause of disability in adults and the aging population There is no cure for OA Current treatments mainly focusing on pain management and improving or sustaining function and have no clearly demonstrated beneficial effect on chondroprotection or OA disease modification Long term use of ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government